{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:27:38Z","timestamp":1793978858254,"version":"4.8.0"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Lupus nephritis (LN), a severe manifestation of systemic lupus erythematosus, requires mycophenolate therapy. This observational study examined the correlation between exposure to mycophenolic acid (MPA) and clinical response in our setting, where therapeutic drug monitoring is not commonly practiced to make a case for its routine availability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>\n                      Adult patients with LN (\u226518 years, histopathological classes III\/IV\/V), receiving standard mycophenolate mofetil (2\u20133 g\/d), were stratified into induction and maintenance cohorts. Blood samples were collected at 0, 1, 2, 4, and 6 hours postadministration to assess MPA exposure (area under the ROC curve [AUC]\n                      <jats:sub>0\u201312<\/jats:sub>\n                      ). The plasma samples were analyzed using high-performance liquid chromatography\u2013ultraviolet detection. The AUC\n                      <jats:sub>(0\u201312)<\/jats:sub>\n                      was estimated using the formula: AUC\n                      <jats:sub>0\u201312)<\/jats:sub>\n                      = AUC\n                      <jats:sub>0-6<\/jats:sub>\n                      +(3*C\n                      <jats:sub>6<\/jats:sub>\n                      ) + (3*C\n                      <jats:sub>0<\/jats:sub>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Of 160 screened participants, 100 were enrolled (induction:\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 44; maintenance:\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 56). Complete and partial renal remission were achieved in 16% and 68% of patients, respectively, in the induction cohort. Higher MPA exposure correlated with sustained reductions in proteinuria. Those with complete renal response demonstrated a higher MPA\u2013AUC\n                      <jats:sub>0\u201312 h<\/jats:sub>\n                      (42.6 \u00b1 24.9 mcg\u00b7h\/mL, 7\/44) compared with the nonresponders (33.1 \u00b1 22.3 mcg\u00b7h\/mL, 7\/44). The mean MPA\u2013AUC\n                      <jats:sub>0\u201312 h<\/jats:sub>\n                      was 36.6 \u00b1 20.3 mcg\u00b7h\/mL in the maintenance cohort, and all 3 relapses occurred at levels considerably below 30 mcg\u00b7h\/mL. The receiver operating characteristic analysis suggested a good discriminatory ability of 30 mcg\u00b7h\/mL as the optimal threshold for inducing remission (AUC = 0.61, 95% CI: 52\u20130.71,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.015), and 24 mcg\u00b7h\/mL for maintaining remission (AUC = 0.91, 95% CI: 0.86\u20130.95,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0001). Most adverse events were mild to moderate in nature, and no serious adverse events were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Our findings demonstrate that variability in MPA exposure significantly impacts treatment response outcomes in LN, reinforcing the clinical utility of therapeutic drug monitoring-guided, individualized mycophenolate mofetil therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001448","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T20:00:17Z","timestamp":1775851217000},"page":"751-761","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Mycophenolic Acid Exposure in Lupus Nephritis: Correlation With Therapeutic Response and Adverse Events to Standard Clinical Dose"],"prefix":"10.1097","volume":"48","author":[{"given":"Ritika","family":"Panwar","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheetal","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Naithani","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeru","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parmeshar Singh","family":"Sidhu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Post Graduate Institute of Medical Education, Research, Chandigarh, India; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhaskar","family":"Krishnamoorthy","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aman","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Rathi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Post Graduate Institute of Medical Education, Research, Chandigarh, India; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5548-4685","authenticated-orcid":false,"given":"Smita","family":"Pattanaik","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"R1-20261106","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/art.37795","article-title":"Epidemiology and sociodemographic of systemic lupus erythematosus and lupus nephritis among US adults with medicaid coverage, 2000\u20132004","volume":"65","author":"Feldman","year":"2013","journal-title":"Arthritis Rheum."},{"key":"R2-20261106","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1177\/0961203308099242","article-title":"Mycophenolate mofetil is effective in reducing disease flares in systemic lupus erythematosus","volume":"18","author":"Nannini","year":"2009","journal-title":"Lupus"},{"key":"R3-20261106","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/01.ASN.0000108969.21691.5D","article-title":"The classification of glomerulonephritis in systemic lupus erythematosus revisited","volume":"15","author":"Weening","year":"2004","journal-title":"J Am Soc Nephrol."},{"key":"R4-20261106","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00003088-200746010-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients","volume":"46","author":"Staatz","year":"2007","journal-title":"Clin Pharmacokinet."},{"key":"R5-20261106","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2215\/CJN.07111009","article-title":"Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation","volume":"5","author":"Kuypers","year":"2010","journal-title":"Clin J Am Soc Nephrol."},{"key":"R6-20261106","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1093\/ndt\/gfm066","article-title":"Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials","volume":"22","author":"Zhu","year":"2007","journal-title":"Nephrol Dial Transpl."},{"key":"R7-20261106","first-page":"1659","article-title":"Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis","volume":"22","author":"Morris","year":"1990","journal-title":"Transpl Proc"},{"key":"R8-20261106","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","article-title":"Mycophenolate mofetil and it's mechanisms of action","volume":"47","author":"Allison","year":"2000","journal-title":"Immunopharmacology"},{"key":"R9-20261106","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/00007691-199512000-00023","article-title":"Mechanism of action of mycophenolate mofetil","volume":"17","author":"Ransom","year":"1995","journal-title":"Ther Drug Monit."},{"key":"R10-20261106","doi-asserted-by":"crossref","first-page":"7630","DOI":"10.4049\/jimmunol.181.11.7630","article-title":"The immunosuppressor mycophenolic acid kills activated lymphocytes by inducing a nonclassical actindependent necrotic signal","volume":"181","author":"Chaigne-Delalande","year":"2008","journal-title":"J Immunol."},{"key":"R11-20261106","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/FTD.0000000000000871","article-title":"Personalized therapy for mycophenolate: consensus report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology","volume":"43","author":"Bergan","year":"2021","journal-title":"Ther Drug Monit."},{"key":"R12-20261106","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1093\/ndt\/gfm308","article-title":"Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisal","volume":"22","author":"Davies","year":"2007","journal-title":"Nephrol Dial Transpl."},{"key":"R13-20261106","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00007691-200502000-00004","article-title":"Cost-effectiveness of therapeutic drug monitoring: a systematic review","volume":"27","author":"Touw","year":"2005","journal-title":"Ther Drug Monit."},{"key":"R14-20261106","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1592\/phco.29.1.7","article-title":"Pharmacokinetics of mycophenolic acid in patients with lupus nephritis","volume":"29","author":"Joy","year":"2009","journal-title":"Pharmacotherapy"},{"key":"R15-20261106","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1097\/01.tp.0000232697.38021.9a","article-title":"Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature","volume":"82","author":"Arns","year":"2006","journal-title":"Transplantation"},{"key":"R16-20261106","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/FTD.0000000000000223","article-title":"Therapeutic drug monitoring of mycophenolic acid in lupus nephritis: a review of current literature","volume":"37","author":"\u0141uszczy\u0144ska","year":"2015","journal-title":"Ther Drug Monit."},{"key":"R17-20261106","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/ki.2010.170","article-title":"Pharmacokinetics of mycophenolic acid in severe lupus nephritis","volume":"78","author":"Lertdumrongluk","year":"2010","journal-title":"Kidney Int."},{"key":"R18-20261106","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/0961203313486949","article-title":"Therapeutic drug monitoring of mycophenolate mofetil for the treatment of severely active lupus nephritis","volume":"22","author":"Kittanamongkolchai","year":"2013","journal-title":"Lupus"},{"key":"R19-20261106","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1002\/art.27495","article-title":"Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil","volume":"62","author":"Zahr","year":"2010","journal-title":"Arthritis Rheum."},{"key":"R20-20261106","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/0961203312469261","article-title":"Concentration-controlled treatment of lupus nephritis with mycophenolate mofetil","volume":"22","author":"Daleboudt","year":"2013","journal-title":"Lupus"},{"key":"R21-20261106","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10067-014-2786-9","article-title":"Optimizing the dose of mycophenolate mofetil for the maintenance treatment of lupus nephritis by therapeutic drug monitoring","volume":"34","author":"Zabotti","year":"2015","journal-title":"Clin Rheumatol."},{"key":"R22-20261106","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/ndt\/gfu184","article-title":"To TDM or not to TDM in lupus nephritis patients treated with MMF?","volume":"30","author":"van Gelder","year":"2015","journal-title":"Nephrol Dial Transpl."},{"key":"R23-20261106","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/FTD.0000000000000031","article-title":"Pharmacokinetics of concentration-controlled mycophenolate mofetil in proliferative lupus nephritis: an observational cohort study","volume":"36","author":"Alexander","year":"2014","journal-title":"Ther Drug Monit."},{"key":"R24-20261106","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1093\/ndt\/gfn360","article-title":"Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil","volume":"23","author":"Neumann","year":"2008","journal-title":"Nephrol Dial Transpl."},{"key":"R25-20261106","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1365-2125.2012.04213.x","article-title":"Population pharmacokinetics of mycophenolic acid and dose optimization with limited sampling strategy in liver transplant children","volume":"74","author":"Barau","year":"2012","journal-title":"Br J Clin Pharmacol."},{"key":"R26-20261106","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","article-title":"2019 update of the joint European League against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis","volume":"79","author":"Fanouriakis","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"R27-20261106","first-page":"288","article-title":"Systemic Lupus Erythematosus Disease Activity Index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol."},{"key":"R28-20261106","first-page":"78","article-title":"A validation study of SLEDAI-2K response index based on data from an observational lupus cohort","volume":"20","author":"Touma","year":"2018","journal-title":"Arthritis Res Ther."},{"key":"R30-20261106","first-page":"139","article-title":"KDIGO clinical practice guideline for glomerulonephritis","volume":"2","year":"2012","journal-title":"Kidney Int Suppl."},{"key":"R31-20261106","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1177\/0961203307084712","article-title":"Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS)","volume":"16","author":"Sinclair","year":"2007","journal-title":"Lupus"},{"key":"R32-20261106","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/FTD.0b013e3181cd550f","article-title":"A reliable limited sampling strategy for the estimation of mycophenolic acid area under the concentration-time curve in adult renal transplant patients in the stable post transplant period","volume":"32","author":"Mathew","year":"2010","journal-title":"Ther Drug Monit."},{"key":"R34-20261106","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/FTD.0000000000001213","article-title":"Population pharmacokinetics and limited sampling strategy of mycophenolate mofetil for Indian patients with lupus nephritis","volume":"46","author":"Koloskoff","year":"2024","journal-title":"Ther Drug Monit."},{"key":"R35-20261106","first-page":"248","article-title":"A six-hour extrapolated sampling strategy for monitoring mycophenolic acid in renal transplant patients in the Indian subcontinent","volume":"52","author":"Fleming","year":"2006","journal-title":"J Postgrad Med."},{"key":"R36-20261106","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/FTD.0b013e3181cd550f","article-title":"A reliable limited sampling strategy for the estimation of mycophenolic acid area under the concentration time curve in adult renal transplant patients in the stable posttransplant period","volume":"32","author":"Mathew","year":"2010","journal-title":"Ther Drug Monit."},{"key":"R37-20261106","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/FTD.0b013e3181d3d051","article-title":"Mycophenolic acid estimation by pooled sampling: a novel strategy","volume":"32","author":"Mathew","year":"2010","journal-title":"Ther Drug Monit."},{"key":"R38-20261106","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3329\/akmmcj.v9i1.35827","article-title":"Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis","volume":"9","author":"Mahmood","year":"2018","journal-title":"Anwer Khan Mod Med Coll J."},{"key":"R39-20261106","doi-asserted-by":"crossref","first-page":"R217","DOI":"10.1186\/ar3202","article-title":"Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study","volume":"12","author":"Djabarouti","year":"2010","journal-title":"Arthritis Res Ther."},{"key":"R40-20261106","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1111\/bcp.12462","article-title":"Pre-dose plasma concentration monitoring of mycophenolate mofetil in patients with autoimmune diseases","volume":"78","author":"Streicher","year":"2014","journal-title":"Br J Clin Pharmacol."},{"key":"R41-20261106","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/0961203312469261","article-title":"Concentration-controlled treatment of lupus nephritis with mycophenolate mofetil","volume":"22","author":"Daleboudt","year":"2013","journal-title":"Lupus"},{"key":"R42-20261106","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/00007890-199609150-00022","article-title":"Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients","volume":"62","author":"Langman","year":"1996","journal-title":"Transplantation"},{"key":"R43-20261106","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00467-003-1133-1","article-title":"Pharmacokinetics of mycophenolate mofetil for autoimmune disease in children","volume":"18","author":"Filler","year":"2003","journal-title":"Pediatr Nephrol."},{"key":"R44-20261106","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00467-020-04733-x","article-title":"Mycophenolic acid area under the concentration-time curve is associated with therapeutic response in childhood-onset lupus nephritis","volume":"36","author":"Godron-Dubrasquet","year":"2021","journal-title":"Pediatr Nephrol."},{"key":"R45-20261106","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/bcp.12678","article-title":"Exposure-effect relationship of mycophenolic acid and prednisolone in adult patients with lupus nephritis","volume":"80","author":"Abd Rahman","year":"2015","journal-title":"Br J Clin Pharmacol."},{"key":"R46-20261106","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1080\/14397595.2019.1623435","article-title":"High plasma mycophenolate acid concentration in the early phase of induction therapy predicts good renal outcome in lupus nephritis","volume":"30","author":"Kiyokawa","year":"2020","journal-title":"Mod Rheumatol."},{"key":"R47-20261106","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/ndt\/gfy284","article-title":"Pharmacokinetics and pharmacogenomics of mycophenolic acid and it's clinical correlations in maintenance immunosuppression for lupus nephritis","volume":"35","author":"Yap","year":"2020","journal-title":"Nephrol Dial Transpl."},{"key":"R48-20261106","first-page":"355","article-title":"Mycophenolic acid plasma trough level: correlation with clinical outcome","volume":"3","author":"Barbari","year":"2005","journal-title":"Exp Clin Transpl."},{"key":"R49-20261106","article-title":"Correlation between area under the concentration\u2013time curve of mycophenolate mofetil and its gastrointestinal tolerability in renal transplant recipients","volume":"35","author":"Kenwar","year":"2025","journal-title":"Indian J Nephrol."},{"key":"R50-20261106","doi-asserted-by":"crossref","first-page":"162","DOI":"10.5414\/CN109583","article-title":"Nephrotic state substantially enhances apparent mycophenolic acid clearance","volume":"91","author":"Kirpalani","year":"2019","journal-title":"Clin Nephrol."},{"key":"R51-20261106","first-page":"1773","article-title":"The role of protein binding in the pharmacokinetics of mycophenolic acid in renal transplant patients","volume":"49","author":"Shipkova","year":"2003","journal-title":"Clin Chem."},{"key":"R52-20261106","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.2215\/CJN.03861106","article-title":"Mycophenolate mofetil: therapeutic drug monitoring of mycophenolic acid","volume":"2","author":"Shaw","year":"2007","journal-title":"Clin J Am Soc Nephrol."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001448","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:01:25Z","timestamp":1793977285000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001448","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"2025-08-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}